Proctocella

ApprovedSmall molecule

UUniversity of Roma La Sapienza

Proctocella is one of 17 small molecule programs targeting Anal fissure. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anal FissureActive, not recruiting

Anal FissureApproved

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Anal Fissure

#DrugCompanyPhaseTrials

Golytely

Bayer

Approved

1 2

Isordil

AstraZeneca

Approved

—3

Chronulac

SSolvay Pharmaceuticals

Approved

1 4

Nitrostat

VViatris Specialty LLC

Phase 3

1 5

Carafate

AbbVie

Phase 2

1 6

Cardizem

BBausch Health Americas, Inc.

Phase 2

2 7

Centella

UUniversity of Roma La Sapienza

Approved

1 8

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—10

Proctocella

UUniversity of Roma La Sapienza

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anal fissure1 trial

Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments

Completed·UUniversity of Roma La Sapienza·Phase 4·NCT03355846·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Proctocella. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Proctocella compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Proctocella. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Roma La Sapienza company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Roma La Sapienza

Proctocella

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anal fissure1 trial

References

Drug Info

Quick Facts

Related News